Taken together, there might be an association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy in HCC and PD-L1 expression might be a valuable predictor of the efficacy of anti-PD-1/PD-L1 therapy in certain patients, however, analyses from especially combination studies showed that patients benefited from immunotherapy regardless of PD-L1 expression level. Here, PDCD1 is linked to hepatocellular carcinoma.